Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects

1994 ◽  
Vol 3 (3) ◽  
pp. 209-224 ◽  
Author(s):  
JE Compston
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Pathogenetic Role ◽  
Duration Of Therapy ◽  
Risks And Benefits ◽  
Oestrogen Deficiency ◽  
Reduce Fracture Risk

The pathogenetic role of oestrogen deficiency in osteoporosis was first postulated by Fuller Albright in 1941 and has subsequently become well established. Hormone replacement therapy prevents menopausal bone loss and is the only treatment which has convincingly been shown to reduce fracture risk at both the spine and hip. The mechanisms by which oestrogens affect bone, however, are poorly understood and many aspects of treatment remain ill-defined, in particular with respect to the duration of therapy and its long-term risks and benefits.

THE LONG-TERM RISKS AND BENEFITS OF HORMONE REPLACEMENT THERAPY

1991 ◽  
Vol 16 (4) ◽  
pp. 231-245 ◽  
Author(s):  
T. C. Hillard ◽  
S. Whitcroft ◽  
M. C. Ellerington ◽  
M. I. Whitehead
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Risks And Benefits

scholarly journals Hormone Replacement Therapy: Risks and Benefits

2020 ◽  
Vol 7 ◽  
Author(s):  
Eriston Vieira Gomes
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Therapeutic Option ◽  
Hormone Replacement ◽  
Medical Practitioner ◽  
Clinical Approach ◽  
Vaginal Atrophy ◽  
Reproductive Senescence ◽  
Risks And Benefits

The climacteric is a physiological period of the female reproductive cycle characterized by a decrease in the levels of sex hormones, mainly estrogen. It consists of several phases, with amenorrhea as the initial clinical manifestation followed by long-term changes, such as vaginal atrophy. In this context, hormone replacement therapy (HRT) aims to improve the symptoms of female reproductive senescence, seeking to provide a comfortable physical and psychological condition during this period. However, as with any drug treatment, HRT has its risks and benefits, and it is up to the medical practitioner, in agreement with the patient, looking for the best therapeutic option, minimizing the risks and consequences resulting from this clinical approach.

scholarly journals Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

2021 ◽  
Vol 81 (05) ◽  
pp. 549-554
Author(s):  
Marina Sourouni ◽  
Ludwig Kiesel
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Current Knowledge ◽  
Hormone Replacement ◽  
Oncological Treatment ◽  
Oncological Safety ◽  
Risks And Benefits ◽  
Gynaecological Malignancy ◽  
Gynaecological Malignancies ◽  
Broad Overview

AbstractRapid advances in oncology have led to an increased survival rate in cancer patients, who live long enough to reach the natural age of menopause or experience the end of gonadal function as a side effect of oncological treatment. Survivors after gynaecological malignancies are a major challenge as these diseases are hormone-dependent and hormone replacement therapy (HRT) possibly increases the risk of recurrence. This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research. The data for assessing the oncological safety of HRT after gynaecological malignancy are insufficient overall. According to current knowledge, HRT is fundamentally contraindicated after breast and endometrial cancer. After ovarian cancer, HRT can be used after assessment of the risks and benefits, while there is usually no contraindication to HRT after vulvar, vaginal or cervical cancer.

Long-term effects of hormone replacement therapy

The Lancet ◽  
2003 ◽  
Vol 361 (9353) ◽  
pp. 254 ◽  
Author(s):  
Norman N Chan ◽  
Peter CY Tong ◽  
CC Chow ◽  
Juliana CN Chan
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Long Term Effects

Risks and Benefits of Hormone Replacement Therapy

Cephalalgia ◽  
2000 ◽  
Vol 20 (3) ◽  
pp. 164-169 ◽  
Author(s):  
B de Lignières ◽  
E A MacGregor
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Mortality And Morbidity ◽  
Oestrogen Deficiency ◽  
Disease Mortality ◽  
Increased Risk ◽  
Deficiency Diseases ◽  
Symptomatic Side ◽  
Natural Progesterone

Menopause, the permanent cessation of menstruation, is due to ovarian failure, which may lead to oestrogen deficiency diseases, particularly osteoporosis, cardiovascular disease and cerebrovascular disease. Mortality and morbidity caused by these conditions can be modified by using hormone replacement therapy, but the benefits of this therapy must be weighed against the increased risk of breast cancer and the symptomatic side-effects the treatment may cause. The combination of transdermal oestrogen and natural progesterone offers the most favourable risk-to-benefit profile.

Sign in / Sign up

Export Citation Format

Share Document